Consensus Statement for the Diagnosis and Treatment of Urticaria: A 2017 Update

被引:46
作者
Godse, Kiran [1 ]
De, Abhishek [2 ]
Zawar, Vijay [3 ]
Shah, Bela [4 ]
Girdhar, Mukesh [5 ]
Rajagopalan, Murlidhar [6 ]
Krupashankar, D. S. [7 ]
机构
[1] DY Patil Hosp, Dept Dermatol, Navi Mumbai, Maharastra, India
[2] Calcutta Natl Med Coll, Dept Dermatol, Kolkata, W Bengal, India
[3] Skin Dis Ctr, Dept Dermatol, Nasik, India
[4] BJ Med Coll, Dept Dermatol, Ahmadabad, Gujarat, India
[5] Max Super Special Hosp, Dept Dermatol, New Delhi, India
[6] Apollo Hosp, Dept Dermatol, Madras, Tamil Nadu, India
[7] Mallige Hosp, Dept Dermatol, Krupa Shankar Skin Care Ctr, Bengaluru, Karnataka, India
关键词
Angioedema; antihistamine; autologous serum therapy; chronic urticaria; cyclosporine; hydroxyzine; Indian guidelines; methotrexate; montelukast; omalizumab; CHRONIC IDIOPATHIC URTICARIA; LEUKOTRIENE RECEPTOR ANTAGONIST; AUTOLOGOUS SERUM THERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND CROSSOVER; MYCOPHENOLATE-MOFETIL; CYCLOSPORINE-A; AUTOIMMUNE URTICARIA; DISEASE-ACTIVITY; WHOLE-BLOOD;
D O I
10.4103/ijd.IJD_308_17
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
This article is developed by the Skin Allergy Research Society of India for an updated evidence-based consensus statement for the management of urticaria, with a special reference to the Indian context. This guideline includes updated definition, causes, classification, and management of urticaria. Urticaria has a profound impact on the quality of life and causes immense distress to patients, necessitating effective treatment. One approach to manage urticaria is by identification and elimination of the underlying cause(s) and/or eliciting trigger(s) while the second one is by treatment for providing symptomatic relief. This guideline recommends the use of second-generation nonsedating H1-antihistamines as the first-line treatment. The dose can be increased up to four times to meet the expected results. In case patients still do not respond, appropriate treatment options can be selected depending on the associated medical condition, severity of the symptoms, affordability of the drugs, and accessibility of modern biologics such as omalizumab.
引用
收藏
页码:2 / 15
页数:14
相关论文
共 96 条
[1]  
Abolnezhadian F, 2016, IRAN J ALLERGY ASTHM, V15, P328
[2]  
[Anonymous], COCHRANE DB SYST REV
[3]  
Asero R, 2010, J INVEST ALLERG CLIN, V20, P386
[4]   Treatment of Refractory Chronic Urticaria: Current and Future Therapeutic Options [J].
Asero, Riccardo ;
Tedeschi, Alberto ;
Cugno, Massimo .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2013, 14 (06) :481-488
[5]   Narrowband ultraviolet B (311 nm, TL01) phototherapy in chronic ordinary urticaria [J].
Aydogan, Kenan ;
Karadogan, Serap Koran ;
Tunali, Sukran ;
Saricaoglu, Hayriye .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2012, 51 (01) :98-103
[6]   Autologous serum therapy in chronic urticaria: Old wine in a new bottle [J].
Bajaj, A. K. ;
Saraswat, Abir ;
Upadhyay, Amitabh ;
Damisetty, Rajetha ;
Dhar, Sandipan .
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2008, 74 (02) :109-113
[7]  
Baskan E Bulbul, 2004, J Dermatolog Treat, V15, P164
[8]   Efficacy of omalizumab in delayed pressure urticaria: a case report [J].
Bindslev-Jensen, C. ;
Skov, P. S. .
ALLERGY, 2010, 65 (01) :138-139
[9]   Consensus meeting on the definition of physical urticarias and urticarial vasculitis [J].
Black, AK ;
Lawlor, F ;
Greaves, MW .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1996, 21 (06) :424-426
[10]   Treatment of Autoimmune Urticaria with Low-dose Cyclosporin A: A One-year Follow-up [J].
Boubouka, Christine ;
Charissi, Christina ;
Kouimintzis, Dimitris ;
Kalogeromitros, Dimitris ;
Stavro-Poulos, Panagiotis ;
Katsarou, Alexandra .
ACTA DERMATO-VENEREOLOGICA, 2011, 91 (01) :50-54